Alliance for Regenerative Medicines’ Seventh
Annual Investors Conference
Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy
company developing a new approach to treating cancer based upon a
novel proprietary technology platform, today announced it will be
presenting at the upcoming Cell & Gene Therapy Investor Day
presented by the Alliance for Regenerative Medicine in New York
City on March 21, 2019.
The one-day investor conference is unique in the medical and
biotech communities as it focuses on fast-paced, concise
presentations from more than 35 companies, fitting them all into a
single-day conference while allowing incredible opportunities for
one-on-one partnering with venture and strategic investors.
Genprex will present at the Seventh Annual ARM Cell &
Gene Therapy Investor Day as follows:
Investor Presentation: Concurrent Tracks, Session 3
Date: Thursday, March 21, 2019
Time: 2:30-2:45 p.m. EDT
Room: Main Bar Room
Venue: Metropolitan Club, One East 60th Street, New York,
NY 10022
For the first time ever, Genprex – an Austin, Texas and
Cambridge, Massachusetts-based biotech company committed to finding
new ways to treat cancer – has been invited to present at the
conference. Rodney Varner, Genprex’s Chairman and Chief Executive
Officer, and Julien Pham, MD, MPH, Genprex’s President and Chief
Operating Officer, will attend the conference on behalf of Genprex.
Dr. Pham will lead the company’s presentation.
“I’m looking forward to attending Cell & Gene Therapy
Investor Day for the first time, with the opportunity to share
information about Genprex’s mission and our gene therapy
technologies,” said Pham. “With a wide array of companies and
industry leaders all presenting in a single day, this conference
enables us and the investment community to take the pulse of where
the industry is heading. It is an incredible honor to be a part of
this event.”
Cell & Gene Therapy Investor Day, produced by the Alliance
for Regenerative Medicine (ARM), an international community of
companies, non-profit research institutions, patient organizations
and other sector stakeholders dedicated to realizing the promise of
regenerative medicine – is an annual conference designed to provide
institutional, strategic and venture investors with unparalleled
insight into financing opportunities for cell and gene
therapy-based treatment and tools. Now in its seventh year, Cell
& Gene Therapy Investor Day is a special, one-day conference
that places an emphasis on brevity in corporate presentations, with
more than 35 companies given 15 minutes each to showcase their
work. More than 175 active investors and analysts will convene in
New York City for the show, which will also feature fireside chats
and expert-led panels, offering unprecedented levels of partnership
opportunities and insight into present and future of regenerative
medicine.
Investors and credentialed media members interested in attending
the event should visit ARM’s website to contact the event's
team.
About Genprex, Inc.
Genprex, Inc. is a clinical stage gene therapy company
developing potentially life-changing technologies for cancer
patients, based upon a unique proprietary technology platform,
including Genprex’s initial product candidate, Oncoprex™ immunogene
therapy for non-small cell lung cancer (NSCLC). Genprex’s platform
technologies are designed to administer cancer fighting genes by
encapsulating them into nanoscale hollow spheres called
nanovesicles, which are then administered intravenously and taken
up by tumor cells where they express proteins that are missing or
found in low quantities. Oncoprex has a multimodal mechanism of
action whereby it interrupts cell signaling pathways that cause
replication and proliferation of cancer cells, re-establishes
pathways for apoptosis, or programmed cell death, in cancer cells,
and modulates the immune response against cancer cells. Oncoprex
has also been shown to block mechanisms that create drug
resistance. Visit the company’s web site at www.genprex.com or
follow Genprex on Twitter at twitter.com/genprex, Facebook at
facebook.com/genprexinc, and LinkedIn at
linkedin.com/company/genprex.
About the Alliance for Regenerative Medicine
The Alliance for Regenerative Medicine (ARM) is the preeminent
international organization focused specifically on the issues
facing regenerative medicine and advanced therapies. It advocates
for progress in gene therapy, cell therapy, and tissue engineering.
Working with its members and policymakers, it fosters investment,
research and development, and successful commercialization of safe,
effective, and transformational therapies for patients around the
world.
In its seventh year, the ARM Cell & Gene Therapy Investor
Day gives investors unmatched insight into the gene therapy
industry. With significant technological advances and a number of
recently approved products, the sector is poised for
ever-increasing investor and analyst interest, and Cell & Gene
Therapy Investor Day serves as the gateway for the investment world
into the sector. The event includes clinical and commercial experts
on-hand to address specific questions regarding the outlook for
products from more than 35 companies, and how this sector is
impacting key therapeutic areas including oncology, ophthalmology,
rare disease, diabetes, cardiovascular disease, wound healing and
tissue repair and neurodegenerative diseases. The program includes
talks by key opinion leaders in the industry, analysts closely
following the sector.
Forward-Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Such
statements include, but are not limited to, statements regarding
the effects of Oncoprex on cancer. Risks and uncertainties
associated with Genprex and its lead product candidate Oncoprex are
described more fully under the caption "Risk Factors" and elsewhere
in our filings and reports with the United States Securities and
Exchange Commission. All forward-looking statements contained in
this press release speak only as of the date on which they were
made. We undertake no obligation to update such statements to
reflect events that occur or circumstances that exist after the
date on which they were made.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190314005055/en/
Genprex, Inc.(877) 774-GNPX (4679)
Investor RelationsGNPX Investor Relations(877) 774-GNPX
(4679) ext. #2investors@genprex.com
Media ContactGenprex Media RelationsKalyn Dabbs(877)
774-GNPX (4679) ext. #3media@genprex.com
Genprex (NASDAQ:GNPX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Genprex (NASDAQ:GNPX)
Historical Stock Chart
From Apr 2023 to Apr 2024